Marc Robillard

Founder at Tagworks Pharmaceuticals BV

Health Technology

Profile

Marc Robillard is associated with Tagworks Pharmaceuticals BV as the founder.
He holds the title of Chief Executive Officer & Director since the company's founding in 2011.

Marc Robillard active positions

Companies	Position	Start
Tagworks Pharmaceuticals BV Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011.	Founder	2010-12-31

All active positions of Marc Robillard

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Marc Robillard's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Tagworks Pharmaceuticals BV Tagworks Pharmaceuticals BV BiotechnologyHealth Technology Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011.	Health Technology